But with the company's market cap still below $1 billion even after the stock's rebound, much larger gains truly could be in store. It will take time for Outset Medical to expand its home dialysis market share. Providers will receive additional payments of up to 8% or reductions in payments of as much as 10% based on their ability to increase home dialysis adoption. Between 20, the ESRD (end-stage renal disease) Treatment Choices Model will use a carrot-and-stick approach to encourage home dialysis. Company Description (How can we help) Contact For technical product support: For order-related questions: For press inquiries: For help with Tablo, please call: (844) MYTABLO (844) 698-2256 DOC-0006333 rev. Outset Medical, Inc.The Ohio State University Fisher College of Business. The picture gets even better for Outset going forward. Outset Medical A new way of experiencing dialysis Tablo is a simple, versatile approach to reducing the cost and complexity of dialysis. Clinical Sales Manager at Outset Medical, Inc. Importantly, the Centers for Medicare and Medicaid Services determined that Tablo offers a "substantial clinical improvement" over older devices. ![]() Several reimbursement changes should boost home use of the device.įor example, in 20, Medicare will pay around $23 to $25 more per treatment for each Tablo home treatment. Outset's prospects appear to be quite bright now that it again has FDA clearance for Tablo to be used in homes.
0 Comments
Leave a Reply. |